1
Clinical Trials associated with Autologous Activated T Lymphocytes(Lukas Biomedical Inc.)A Phase II Study to Evaluate the Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (HCC) Patients After Curative Treatment
This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).
100 Clinical Results associated with Autologous Activated T Lymphocytes(Lukas Biomedical Inc.)
100 Translational Medicine associated with Autologous Activated T Lymphocytes(Lukas Biomedical Inc.)
100 Patents (Medical) associated with Autologous Activated T Lymphocytes(Lukas Biomedical Inc.)
100 Deals associated with Autologous Activated T Lymphocytes(Lukas Biomedical Inc.)